Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells 14,257 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the sale, the chief operating officer now directly owns 635,363 shares of the company’s stock, valued at approximately $40,129,527.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Muthusamy Shanmugam also recently made the following trade(s):

• On Monday, July 15th, Muthusamy Shanmugam sold 11,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.38, for a total value of $697,180.00.
• On Friday, June 21st, Muthusamy Shanmugam sold 20,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $58.90, for a total transaction of $1,178,000.00.
• On Monday, May 20th, Muthusamy Shanmugam sold 12,855 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $61.81, for a total transaction of $794,567.55.
• On Friday, May 17th, Muthusamy Shanmugam sold 5,836 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $62.09, for a total transaction of $362,357.24.
• On Wednesday, May 15th, Muthusamy Shanmugam sold 14,850 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.86, for a total value of $978,021.00.
• On Friday, April 19th, Muthusamy Shanmugam sold 16,809 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.17, for a total transaction of $1,095,442.53.

ANI Pharmaceuticals Stock Down 1.9 %

Shares of NASDAQ ANIP traded down $1.25 during mid-day trading on Wednesday, hitting $62.98. The company had a trading volume of 186,851 shares, compared to its average volume of 147,298. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63. The firm has a 50-day simple moving average of $63.29 and a two-hundred day simple moving average of $62.58. The company has a market capitalization of $1.32 billion, a PE ratio of 39.36 and a beta of 0.75. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.16. The firm had revenue of $137.43 million during the quarter, compared to the consensus estimate of $125.01 million. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.32 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP increased its holdings in shares of ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after acquiring an additional 277,989 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock worth $65,746,000 after buying an additional 58,204 shares during the period. Global Alpha Capital Management Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 10.8% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after acquiring an additional 56,900 shares during the period. Assenagon Asset Management S.A. grew its position in shares of ANI Pharmaceuticals by 121.3% in the first quarter. Assenagon Asset Management S.A. now owns 83,944 shares of the specialty pharmaceutical company’s stock valued at $5,803,000 after purchasing an additional 46,008 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 6.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after purchasing an additional 33,359 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ANIP. HC Wainwright boosted their price target on ANI Pharmaceuticals from $87.00 to $94.00 and gave the company a “buy” rating in a report on Wednesday, June 26th. Guggenheim reaffirmed a “buy” rating and set a $77.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $82.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.